Last reviewed · How we verify
Transdermal Glucosamine Cream
Transdermal glucosamine cream delivers glucosamine through the skin to support cartilage structure and reduce joint inflammation.
Transdermal glucosamine cream delivers glucosamine through the skin to support cartilage structure and reduce joint inflammation. Used for Osteoarthritis pain and joint support.
At a glance
| Generic name | Transdermal Glucosamine Cream |
|---|---|
| Also known as | TGC® Plus Capsaicin |
| Sponsor | Lynk Biotechnologies Pte Ltd |
| Drug class | Topical joint support agent |
| Modality | Small molecule |
| Therapeutic area | Orthopedics / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Glucosamine is an aminomonosaccharide that serves as a precursor for glycosaminoglycans and proteoglycans, key structural components of cartilage. When applied topically, it is intended to penetrate the skin and reach affected joints, where it may stimulate cartilage synthesis and reduce degradation. The transdermal formulation aims to provide localized delivery while potentially reducing systemic exposure compared to oral glucosamine.
Approved indications
- Osteoarthritis pain and joint support
Common side effects
- Skin irritation or rash at application site
- Local itching or burning
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transdermal Glucosamine Cream CI brief — competitive landscape report
- Transdermal Glucosamine Cream updates RSS · CI watch RSS
- Lynk Biotechnologies Pte Ltd portfolio CI